Physician profile
David Hall
NPI 1023068582
$5,171.95
in general payments reported to CMS, 2019-2025
36 companies · $1,483 in 2025
The $1,483 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $627 · 2020: $185 · 2021: $143 · 2022: $523 · 2023: $1,072 · 2024: $1,139 · 2025: $1,483.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,695.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,694.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $694.46 | 2019-2025 | Xtandi, Myrbetriq |
| Pfizer INC. | $552.81 | 2019-2025 | |
| Journey Medical Corporation | $539.06 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $449.36 | 2023-2025 | Orgovyx, Gemtesa |
| Dendreon Pharmaceuticals LLC | $370.58 | 2024-2025 | Provenge |
| Janssen Biotech, INC. | $299.85 | 2020-2025 | Erleada |
| Tolmar, INC. | $224.09 | 2023-2025 | Eligard, Jatenzo |
| Myriad Genetic Laboratories, INC. | $175.60 | 2020-2024 | Prolaris |
| Abbvie INC. | $166.30 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $142.42 | 2019-2025 | |
| Coloplast Corp | $128.61 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $126.47 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $126.03 | 2020-2024 | Welireg, Keytruda, Lynparza |
| Cumberland Pharmaceuticals, INC. | $99.98 | 2019-2023 | Caldolor |
| Antares Pharma, INC. | $98.81 | 2019-2024 | Xyosted, Tlando, Nocdurna |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Procept Biorobotics Corporation | $94.71 | 2019-2025 | Aquabeam Robotic System |
| Accord Healthcare, INC. | $92.90 | 2022-2023 | |
| Ferring Pharmaceuticals INC. | $92.23 | 2019-2025 | Adstiladrin |
| Boston Scientific Corporation | $85.71 | 2019-2024 | Ams 700 |
| Telix Pharmaceuticals | $83.57 | 2025 | Illuccix |
| Axonics, INC. | $79.36 | 2021-2024 | Axonics |
| Urogen Pharma, INC. | $67.70 | 2022-2025 | Jelmyto |
| Progenics Pharmaceuticals, INC. | $49.99 | 2023-2025 | Pylarify |
| Tolmar Pharmaceuticals, INC. | $48.98 | 2020-2022 | |
| Myovant Sciences INC. | $45.62 | 2021-2022 | |
| Genzyme Corporation | $37.12 | 2020-2023 | |
| Davol INC. | $33.28 | 2024 | Arista Ah Flexitip |
| Halozyme INC | $26.23 | 2023 | |
| Agiliti Surgical, INC. | $24.29 | 2023 | Trinity, Cryocare Cs, Sonablate |
| Immunitybio, INC. | $23.83 | 2025 | |
| Teleflex LLC | $19.71 | 2025 | Barrigel |
| Angiodynamics, INC. | $16.51 | 2023 | Nanoknife |
| Verity Pharmaceuticals INC. | $15.44 | 2025 | Trelstar |
| Laborie Medical Technologies Corp. | $14.81 | 2024 | Optilume Bph Drug Coated Balloon Catheter |
| Provepharm INC. | $14.29 | 2025 | Bludigo |
| Metuchen Pharmaceuticals | $11.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Hall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.